In a report released yesterday, Amit Daryanani from Evercore ISI maintained a Buy rating on Vertiv Holdings (VRT – Research Report), with a ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...

Evercore ISI began coverage on Flowco Holdings (NYSE:FLOC), assigning the stock an Outperform rating and setting a price target of $35.00. Currently trading at $28.65, near its 52-week high of $30.50, ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on CVS Health (CVS – Research Report), with a ...

Vera Therapeutics (VERA) stock falls as Otsuka (OTSKF) updates on its IgA nephropathy therapy sibeprenlimab, which rivals ...

The Carlyle Group (NASDAQ:CG – Get Free Report) had its price target hoisted by analysts at Evercore ISI from $51.00 to $52.00 in a report issued on Wednesday,Benzinga reports. The firm presently has ...

UDR (NYSE:UDR – Get Free Report) had its price objective upped by research analysts at Evercore ISI from $43.00 to $45.00 in a research report issued on Monday,Benzinga reports. The firm presently has ...

Evercore ISI upgraded Marriott International (MAR, Financials) to Outperform from In-Line, citing robust travel demand, the ...

Ari Bousbib; Chairman of the Board, Chief Executive Officer; IQVIA Holdings Inc Ronald Bruehlman; Chief Financial Officer, Executive Vice President; IQVIA Holdings Inc Shlomo Rosenbaum; Analyst; ...